Abstract
The clinical benefit of suicide gene therapy of tumors has been marginal, mostly due to the low gene transfer efficiency in vivo. The death-inducing ligand, TRAIL, effectively kills many tumor cell types, while sparing most normal tissues. We hypothesized that TRAIL may enhance HSV thymidine kinase/ganciclovir (TK/GCV) gene therapy of tumor cells by augmenting both target and bystander cell kill. Human SH-EP neuroblastoma cells expressing TK as well as bystander cells were effectively killed by apoptosis, and their clonogenicity was ablated following GCV. Human TRAIL enhanced TK/GCV–induced cell death and decreased clonogenicity of TK-expressing cells and also of bystander cells. Cooperation between TRAIL and TK/GCV depended both on caspase activation and on mitochondrial apoptogenic function because both the broad-spectrum caspase inhibitor zVAD.fmk and overexpression of Bcl-2 decreased enhancement of cell kill by TRAIL. Facilitation of TRAIL signalling by up-regulation of TRAIL receptors did not contribute to enhancement because cell surface expression of the agonistic TRAIL receptors 1 and 2 was not increased by TK/GCV. In conclusion, the concerted activation of caspases and the mitochondrial amplification of caspase activation by TK/GCV may explain the cooperative effect of TK/GCV and TRAIL on the kill of neuroblastoma cells. Because combined treatment also augmented the bystander cell kill, the addition of TRAIL may increase the efficacy of TK/GCV gene therapy of neuroblastoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ashkenazi A, Dixit VM . Apoptosis control by death and decoy receptors Curr Opin Cell Biol 1999 11: 255–260
Beltinger C, Fulda S, Kammertoens T, Meyer E, Uckert W, Debatin KM . Herpes simplex virus thymidine kinase/ganciclovir–induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases Proc Natl Acad Sci USA 1999 96: 8699–8704
Beltinger C, Fulda S, Kammertoens T, Uckert W, Debatin KM . Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir–triggered activation of apoptosis Cancer Res 2000 60: 3212–3217
Beltinger C, Uckert W, Debatin KM . Suicide gene therapy for pediatric tumors J Mol Med 2001 78: 598–612
Benedetti S, Dimeco F, Pollo B et al. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene Hum Gene Ther 1997 8: 1345–1353
Bi WL, Parysek LM, Warnick R, Stambrook PJ . In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy Hum Gene Ther 1993 4: 725–731
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage Science 1984 224: 1121–1124
Chinnaiyan AM, Prasad U, Shankar S et al. Combined effect of tumor necrosis factor–related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy Proc Natl Acad Sci USA 2000 97: 1754–1759
Dejosez M, Ramp U, Mahotka C et al. Sensitivity to TRAIL/APO-2L–mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan Cell Death Differ 2000 7: 1127–1136
Denizot F, Lang R . Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J Immunol Methods 1986 89: 271–277
Fletcher C, Sawchuk R, Chinnock B, de Miranda P, Balfour HH Jr . Human pharmacokinetics of the antiviral drug DHPG Clin Pharmacol Ther 1986 40: 281–286
Freeman SM, Abboud CN, Whartenby KA et al. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified Cancer Res 1993 53: 5274–5283
Friedmann T, Yee J-K . Pseudotyped retroviral vectors for studies of human gene therapy Nat Med 1995 1: 275–277
Fulda S, Susin SA, Kroemer G, Debatin KM . Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells Cancer Res 1998 58: 4453–4460
Gliniak B, Le T . Tumor necrosis factor–related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11 Cancer Res 1999 59: 6153–6158
Gong B, Almasan A . Apo2 ligand/TNF–related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells Cancer Res 2000 60: 5754–5760
Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL . Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis J Immunol 2000 165: 2886–2894
Hakumaki JM, Poptani H, Puumalainen AM et al. Quantitative 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase–mediated gene therapy in vivo: identification of apoptotic response Cancer Res 1998 58: 3791–3799
Hamel W, Magnelli L, Chiarugi VP, Israel MA . Herpes simplex virus thymidine kinase/ganciclovir–mediated apoptotic death of bystander cells Cancer Res 1996 56: 2697–2702
Hinz S, Trauzold A, Boenicke L et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor–mediated apoptosis Oncogene 2000 19: 5477–5486
Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N . Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor–related apoptosis-inducing ligand-induced apoptosis Cancer Res 2000 60: 4315–4319
Isaacs JS, Hardman R, Carman TA, Barrett JC, Weissman BE . Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines Cell Growth Differ 1998 9: 545–555
Jo M, Kim TH, Seol DW et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor–related apoptosis-inducing ligand Nat Med 2000 6: 564–567
Kagawa S, He C, Gu J et al. Antitumor activity and bystander effects of the tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) gene Cancer Res 2001 61: 3330–3338
Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S . Chemotherapy augments TRAIL-induced apoptosis in breast cell lines Cancer Res 1999 59: 734–741
Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A . Apo2L/TRAIL–dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5 Immunity 2000 12: 611–620
Klatzmann D, Valery CA, Bensimon G et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Study group on gene therapy for glioblastoma Hum Gene Ther 1998 9: 2595–2604
Kuriyama S, Kikukawa M, Masui K et al. Cancer gene therapy with HSV-tk/GCV system depends on T-cell–mediated immune responses and causes apoptotic death of tumor cells in vivo Int J Cancer 1999 83: 374–380
Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT . Anticancer agents sensitize tumor cells to tumor necrosis factor–related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis Cancer Res 2001 61: 1645–1651
Leverkus M, Neumann M, Mengling T et al. Regulation of tumor necrosis factor–related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes Cancer Res 2000 60: 553–559
Mariani SM, Matiba B, Armandola EA, Krammer PH . Interleukin 1 beta–converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells J Cell Biol 1997 137: 221–229
Maris JM, Matthay KK . Molecular biology of neuroblastoma J Clin Oncol 1999 17: 2264–2279
Melcher A, Gough M, Todryk S, Vile R . Apoptosis or necrosis for tumor immunotherapy: what's in a name? J Mol Med 1999 77: 824–833
Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG . Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression Nat Med 1998 4: 581–587
Mesnil M, Yamasaki H . Bystander effect in herpes simplex virus–thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication Cancer Res 2000 60: 3989–3999
Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ . Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor–related apoptosis-inducing ligand in vitro and in vivo Cancer Res 2000 60: 847–853
Nagata S . Fas ligand–induced apoptosis Annu Rev Genet 1999 33: 29–55
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C . A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry J Immunol Methods 1991 139: 271–279
Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN . Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor–related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels Cancer Res 2001 61: 759–763
Nitsch R, Bechmann I, Deisz RA et al. Human brain-cell death induced by tumour-necrosis-factor–related apoptosis-inducing ligand (TRAIL) Lancet 2000 356: 827–828
Sheikh MS, Burns TF, Huang Y et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha Cancer Res 1998 58: 1593–1598
Takeda K, Hayakawa Y, Smyth MJ et al. Involvement of tumor necrosis factor–related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells Nat Med 2001 7: 94–100
Teitz T, Wei T, Valentine MB et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN Nat Med 2000 6: 529–535
Uckert W, Kammertons T, Haack K et al. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo Hum Gene Ther 1998 9: 855–865
Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H . Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile ofintratumoural cytokine expression Int J Cancer 1997 71: 267–274
Vile RG, Russell SJ, Lemoine NR . Cancer gene therapy: hard lessons and new courses Gene Ther 2000 7: 2–8
Walczak H, Bouchon A, Stahl H, Krammer PH . Tumor necrosis factor–related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2– or Bcl-xL–overexpressing chemotherapy-resistant tumor cells Cancer Res 2000 60: 3051–3057
Walczak H, Degli-Esposti MA, Johnson RS et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL EMBO J 1997 16: 5386–5397
Walczak H, Krammer PH . The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems Exp Cell Res 2000 256: 58–66
Walczak H, Miller RE, Ariail K et al. Tumoricidal activity of tumor necrosis factor–related apoptosis-inducing ligand in vivo Nat Med 1999 5: 157–163
Wei SJ, Chao Y, Shih YL, Yang DM, Hung YM, Yang WK . Involvement of Fas (CD95/APO-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinase Gene Ther 1999 6: 420–431
Wu GS, Burns TF, McDonald ER et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene Nat Genet 1997 17: 141–143
Acknowledgements
We thank W Uckert for advice. The skillful technical assistance of H Knauss is appreciated. This work has been partially supported by grants to CB and KMD from the Deutsche Krebshilfe. Presented, in part, at the 92nd annual meeting of the American Association for Cancer Research, New Orleans, 2001.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beltinger, C., Fulda, S., Walczak, H. et al. TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells. Cancer Gene Ther 9, 372–381 (2002). https://doi.org/10.1038/sj.cgt.7700448
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700448
Keywords
This article is cited by
-
Nucleic acid drug vectors for diagnosis and treatment of brain diseases
Signal Transduction and Targeted Therapy (2023)
-
Enriching suicide gene bearing tumor cells for an increased bystander effect
Cancer Gene Therapy (2007)
-
Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas
Gene Therapy (2007)
-
AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression
Gene Therapy (2004)